Research Projects Page

Since our inception as an outcome committee in 2015, we have consistently and considerably expanded our ability to produce rigorous outcomes research. In 2018, we established a more formal program and leadership, including full time outcomes research staff. The result of these allocated resources has been a productive output across multiple specialty disease states. Below are highlighted outcomes from studies completed in recent years. 

To see our full bibliography, Click Here

Research Project List

Filter
Research categories (field_research_categories)
Research categories (field_research_categories)
112 Results

Impact of an Integrated Specialty Pharmacy Model on Patient Access to Dalfampridine

Published March 24, 2022
Featured
This study compared patient access to dalfampridine before versus after Vanderbilt Specialty Pharmacy obtained access to dispense the drug. Findings highlight how integrated specialty pharmacists can provide effective medication monitoring, counseling, and access when limited distribution networks are removed.
View Poster. March 2022
Download Publication

A targeted approach to reducing rates of discontinuation and dose reduction in patients receiving sorafenib or regoranfenib

Published March 23, 2022
Featured
Sorafenib and regorafenib are oral multikinase inhibitors used to treat some cancers, but adverse events for both drugs are common and often cause patients to discontinue therapy or reduce their dose within several months of initiating therapy. This study found that a pharmacist-initiated tailored intervention reduced sorafenib and regorafenib discontinuations (29% to 13%) and dose reductions due to adverse reactions (18% to 13%).
View Poster. March 2022

Specialty Medication Adherence Rates in Patients with Rheumatoid Arthritis across Health-System Specialty Pharmacies

Published March 22, 2022
Featured
This study evaluated rates of adherence to biologic DMARDS, measured by PDC, across 20 health-system specialty pharmacies through the Health-System Specialty Pharmacy Outcomes Research Consortium. High rates of adherence to biologic DMARDs were seen across 20 health-systems specialty pharmacies, demonstrating the benefits of health-system specialty pharmacies in helping patients with RA remain on effective therapies.
View Poster. March 2022
Download Publication

Implementation of a Standardized Specialty Pharmacist Documentation Tool Within the Electronic Health Record in an Integrated Outpatient Dermatology Clinic

Published January 5, 2023
We implemented a standardized documentation tool (SmartForms) that would collect discrete data fields during the specialty pharmacist's workflow in Dermatology clinic. This allowed us to collect data for reporting purposes on the front end, save time, document pharmacist interventions prior to treatment initiation, improve Epic documentation visibility and future usability.
View Poster. January 2023

Assessing Patient-Reported Outcomes within an Integrated Health System Specialty Pharmacy

Published December 9, 2022
This study collected patient-reported side effects, missed doses, and perceived medication effectiveness for 1,398 patients over 3 months. Patient-reported side effects impact adherence and perceived medication effectiveness. Patients filling specialty medications within an integrated health system specialty pharmacy reported low rates of missed doses and side effects.
View Poster. December 2022

Persistence of Vesicular Monoamine Transport 2 Inhibitor Therapy for Tourette Syndrome and Chronic Tic Disorders

Published November 28, 2022
Persistence of Vesicular Monoamine Transport 2 Inhibitor Therapy for Tourette Syndrome and Chronic Tic Disorders
View Poster. November 2022

Assessing Patient-reported Outcomes and Pharmacist Interventions in Patients Prescribed Specialty Medications for Dermatology and Asthma, Sinus, and Allergy

Published November 22, 2022
Patient reported outcomes can be used to measure therapeutic response, as well as overall health status, functioning, quality of life, and disease management. Patients with inflammatory conditions who fill medication within an integrated HSSP model reported low rates of missed doses and side effects, and most rated high perceived medication effectiveness.
View Poster. November 2022

Assessing Patient-Reported Outcomes and Pharmacist Interventions in Multiple Sclerosis within an Integrated Care Center

Published November 22, 2022
The objective of this study was to assess PROs and pharmacist interventions in patients prescribed specialty MS medications at a health system with an integrated specialty pharmacy. We concluded that patients filling medication from our integrated health system specialty pharmacy model reported low rates of missed doses and side effects, and most rated high perceived effective medication use.
View Poster. November 2022
Research Bibliography